TD Cowen analyst Joshua Jennings lowered the firm’s price target on Humacyte (HUMA) to $7.50 from $10 and keeps a Buy rating on the shares. The firm noted Humacyte hosted an investor event that included an update on positive early US Vascular Trauma launch trends and strong feedback from vascular surgeons who have experience with Symvess. Management also reported on the AV Access clinical development program and the new BLA filing timeline.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte announces publication of Budget Impact Model for Symvess
- Humacyte’s SYMVESS Launch and Strategic Positioning Drive Buy Rating
- Largest borrow rate increases among liquid names
- Promising Future for Humacyte: Strategic Collaborations and Innovative Developments Drive Growth Potential
- Humacyte, Trestle Biotherapeutics announce research collaboration
Questions or Comments about the article? Write to editor@tipranks.com